In large cardiovascular (CV) outcome trials of patients with type 2 diabetes (T2D), sodium–glucose co-transporter 2 (SGLT2) inhibitors have demonstrated beneficial effects on CV outcomes.

These results have been presented in a recent ESC conference and published on scientific journals.

Baseline characteristics of participants enrolled in different trials have also been described and analysed in a recent paper published last week on NDT.
Read the article here.

These new data demonstrate effectiveness and safety of this new class of drugs